25 May 2013
Keywords: India, Obesity, Tuberculosis, Rimonabant, Sanofi-Aventis
Article | 04 January 2010
After almost 10 months since India’s Drugs Technical Advisory Board (DTAB) recommended its prohibition following reports of various side effects, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
4 January 2010
24 May 2013
© 2013 thepharmaletter.com